Researchers used gilteritinib to target a common mutation -- ScienceDaily

A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn’s Abramson Cancer Center. The Fms-like tyrosine kinase...

Read full post here:
https://skpsoft.com/business/researchers-used-gilteritinib-to-target-a-common-mutation-sciencedaily/